NP_036584
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
19,865 Da
NCBI Official Full Name
tumor necrosis factor receptor superfamily member 13B
NCBI Official Synonym Full Names
tumor necrosis factor receptor superfamily, member 13B
NCBI Official Synonym Symbols
CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B [Similar Products]
NCBI Protein Information
tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor
UniProt Protein Name
Tumor necrosis factor receptor superfamily member 13B
UniProt Synonym Protein Names
Transmembrane activator and CAML interactor; CD_antigen: CD267
UniProt Synonym Gene Names
UniProt Entry Name
TR13B_HUMAN
NCBI Summary for TNFRSF13B
The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
UniProt Comments for TNFRSF13B
TNFRSF13B: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T- cell function and the regulation of humoral immunity. Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2). CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2). Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Cell cycle regulation; Membrane protein, integral; Receptor, misc.
Chromosomal Location of Human Ortholog: 17p11.2
Cellular Component: integral to plasma membrane; external side of plasma membrane
Molecular Function: protein binding; receptor activity
Biological Process: cell surface receptor linked signal transduction; B cell homeostasis; hemopoietic progenitor cell differentiation; negative regulation of B cell proliferation
Disease: Immunodeficiency, Common Variable, 2; Immunoglobulin A Deficiency 2
Research Articles on TNFRSF13B
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-TNFRSF13B antibody
Pathways associated with anti-TNFRSF13B antibody
Diseases associated with anti-TNFRSF13B antibody
Organs/Tissues associated with anti-TNFRSF13B antibody
|